Inhibition of the oncogenic GTPase dynamin-related protein 1 (DRP1) by the FDA-approved drug fosaprepitant: In silico, biophysical, and in vitro characterization of its anti-myeloma activity Emanuela Marchese, Pierpaolo Murfone, Ilenia Valentino, Maria Eugenia Gallo Cantafio, Francesca Alessandra Ambrosio, Irene Gado, Noemi Puccio, Massimo Gentile, Antonino Neri, Giuseppe Viglietto, Stefano Alcaro, Francesca Vasile, Giosuè Costa, Nicola Amodio International Journal of Biological Macromolecules, 2026 Mitochondrial fission plays a crucial role in sustaining cellular homeostasis, and disturbances in this process have been linked to numerous pathological conditions, including cancer. The central regulator of mitochondrial division is the large GTPase dynamin-related protein 1 (DRP1), whose enzymatic activity drives the constriction and separation of mitochondria. Given its pivotal function, DRP1 has gained attention as a potential oncogenic target across several cancer types. However, the availability of small-molecule inhibitors targeting DRP1 remains limited. To discover novel inhibitors, we performed a virtual screening campaign of FDA-approved drugs obtained from the DrugBank database, leading to the identification of three compounds predicted to interact with the GTPase domain of DRP1. Among these, the antiemetic agent fosaprepitant emerged as a promising hit. Computational docking and GTPase activity assays supported its inhibitory potential, which was further confirmed through saturation transfer difference nuclear magnetic resonance (STD-NMR) spectroscopy, demonstrating direct binding between fosaprepitant and DRP1 and elucidating key contact sites. Consistent with inhibition of mitochondrial fission, fosaprepitant treatment in multiple myeloma (MM) cell lines induced mitochondrial hyperfusion, decreased cell viability and colony formation in a DRP1-dependent manner, and disrupted oxidative phosphorylation (OXPHOS), ultimately leading to mitochondrial dysfunction and apoptotic cell death. Overall, this study provides a robust platform for the identification of novel DRP1 inhibitors among FDA-approved compounds, highlighting fosaprepitant as a promising candidate for drug repurposing with anti-cancer potential.
MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma María Labrador, Sara Cozzubbo, Mariangela Porro, Michela Cumerlato, Cecilia Bandini, Elisabetta Mereu, Tina Paradzik, Benedetta Donati, Veronica Manicardi, Domenica Ronchetti, Mattia D’Agostino, Alessandra Larocca, Francesca Gay, Benedetto Bruno, Alessia Ciarrocchi, Andrew Chatr-Aryamontri, Antonino Neri, Eugenio Morelli, Roberto Piva Cells, 2026 Proteasome inhibitors (PIs) are central to multiple myeloma (MM) therapy; however, resistance remains a major clinical challenge, particularly in relapsed/refractory disease. To identify functional mediators of carfilzomib (CFZ) resistance, we performed complementary gain-of-function CRISPR activation and pharmacological screening approaches. These unbiased strategies converged on the E3 ubiquitin ligase MDM2 as a modulator of PI response. MDM2 transactivation enhanced MM cell survival and accelerated recovery following CFZ exposure, supporting a causal role in proteotoxic stress tolerance. Pharmacologic inhibition of MDM2 with NVP-CGM097 synergized with CFZ across multiple PI-sensitive and PI-resistant MM cell lines, irrespective of TP53 status. Mechanistically, MDM2 inhibition induced p21 upregulation, cell-cycle arrest, and reduced c-MYC expression, accompanied by impaired activation of DNA damage response mediators. Genetic silencing of MDM2 phenocopied these effects and increased CFZ sensitivity. Importantly, the combination retained efficacy in MM–stromal co-culture models and in primary patient samples, including cases harboring del(17p), while sparing normal peripheral blood mononuclear cells. Collectively, these findings identify MDM2 as a functional driver of PI resistance and support combined MDM2 and proteasome inhibition as a rational therapeutic strategy in MM, including TP53-deficient contexts.
Identification of ceRNA Regulatory Networks Driven by the lncRNA NEAT1 in Multiple Myeloma Domenica Ronchetti, Valentina Traini, Ilaria Silvestris, Giuseppina Fabbiano, Andrea Devecchi, Federica Torricelli, Noemi Puccio, Ilaria Craparotta, Marco Bolis, Roberto Piva, Antonino Neri, Luca Agnelli, Francesco Passamonti, Niccolò Bolli, Elisa Taiana Journal of Cellular and Molecular Medicine, 2026 The lncRNA NEAT1 is overexpressed in multiple myeloma (MM) plasma cells and plays a key role in MM pathogenesis. NEAT1 is involved in ceRNA network in several cancers; however, data in MM are virtually absent. This study identified a NEAT1‐driven ceRNA network involving 96 miRNAs and 40 target genes, selected as concurrently downregulated in NEAT1‐KD AMO1 cells and upregulated in NEAT1‐overexpressing AMO1 cells (AMO1‐OVX). The co‐expression of NEAT1 and the targets was validated in MM patients (GSE116294, GSE13591, GSE6477, CoMMpass), and in NEAT1‐KD NCI‐H929, LP1, and KMS27 cell lines, showing for all targets a consistent downregulation, resembling that of NEAT1. The functional implication of the ceRNA network was explored by functional enrichment analyses of the 40 targets, identifying 78 significant gene sets, 17 of which were found significantly enriched by GSEA analysis in at least one experimental condition among NEAT1‐KD LP1, NCI‐H929, and KMS27 cells, AMO1‐OVX cells, or the extreme quartiles of NEAT1 expression in the CoMMpass dataset. Noteworthy, the cell cycle gene set was validated in 5 out of 6 conditions tested, suggesting that in MM the impact of NEAT1 upregulation on the cell cycle, experimentally demonstrated in our earlier publications, may be attributable, at least partially, to ceRNA mechanisms.
FcγRIIIA Genotype in Plasma Cell Dyscrasias Is Associated with Clinical Progression, Bone Disease Extension and Immune Dysfunction Daniela Cambria, Maria Teresa Cannizzaro, Nunziatina Laura Parrinello, Sara Marino, Ilaria Dulcamare, Noemi Puccio, Federica Torricelli, Marta Lionetti, Deborah Calvo, Mohammadreza Khosropoor, Concetta Conticello, Francesco Di Raimondo, Lavinia Raimondi, Gianluca Giavaresi, Cirino Botta, Antonino Neri, Alessandra Romano Cancers, 2026 Background/Objectives: FcγRIIIA presents a single nucleotide polymorphism at position 158 (V/F), which affects its binding affinity to the fragment crystallizable (Fc) of antibodies (Abs). In the presence of immune complexes, FcγRIIIA can mediate the inflammatory signaling, severity of bone disease, and osteoclastogenic activity. Based on this functional relevance, we hypothesized that the FcγRIIIA F158V polymorphism may influence the clinical presentation of multiple myeloma (MM). Methods: FcγRIIIA F158V genotyping was performed on genomic DNA extracted from peripheral blood samples of patients affected by MM or asymptomatic conditions named MGUS and SMM. We compared the allele frequency of FcγRIIIA-F158V polymorphism in 72 MM, 42 MGUS and 31 SMM and evaluated the association with clinical features and occurrence of high-risk chromosome abnormalities. Targeted NGS mutation analysis was performed on genomic DNA isolated from purified CD138+ bone marrow plasma cells (BMPCs) of 41 patients, to evaluate the association between somatic mutations and the FcγRIIIA F158V genotype. Results: the FcγRIIIA-158 V/V homozygous genotype was associated with high-risk cytogenetics, anemia, high beta-2 microglobulin levels, and more than 10 osteolytic lesions. V/V homozygous genotype was significantly associated with at least one mutation in RAS pathway genes (N-RAS, K-RAS or B-RAF). In the immune microenvironment, patients carrying the V/V homozygous genotype had a higher percentage of CD14+CD16++ non-conventional inflammatory monocytes than the V/F or FF genotype. Conclusions: Our study contributes to a better understanding of the interactions between genetic variants, tumor microenvironment, and therapeutic response in plasma cell dyscrasias, to identify molecular biomarkers for precision medicine in MM, MGUS and SMM.
Immunogenetic Architecture of Chronic Lymphocytic Leukemia at Early Stage: Insights from the O-CLL1 Cohort Davide Bagnara, Andrea Nicola Mazzarello, Monica Colombo, Ennio Nano, Niccolò Cardente, Fabiana Ferrero, Nadia Bertola, Vanessa Cossu, Fabio Ghiotto, Adalberto Ibatici, Emanuele Angelucci, Antonino Neri, Massimo Gentile, Fortunato Morabito, Manlio Ferrarini, Giovanna Cutrona, Franco Fais Antibodies, 2026 Background/Objectives: The immunoglobulin heavy-chain variable (IGHV) gene repertoire represents a characteristic feature of chronic lymphocytic leukemia (CLL), although its configuration is not well defined at the early disease stages. The IGHV repertoire of a cohort of early CLL patients was analyzed and compared to that of a “real-world” reference cohort. Methods: Patients from the O-CLL1 observational protocol, which enrolled only Binet stage A cases within twelve months from diagnosis, were studied. IGHV/IGHJ rearrangements were sequenced and annotated following ERIC recommendations, and stereotyped subsets were assigned using ARResT/AssignSubsets. The repertoire features were compared with the dataset of a real-world cohort of patients with heterogeneous staging (CTR cohort) and with published early-diagnosis series. Results: IGHV and IGHJ gene distributions and HCDR3-length profiles in O-CLL1 closely mirrored those of CTR, indicating that the BcR IG repertoire at diagnosis is already defined rather than being selected during disease progression. Mutated IGHV (M-CLL) predominated, with a frequency of stereotyped BcR IG comparable to that of other early-diagnosis cohorts. However, within this conserved framework, subset #4 was over-represented among M-CLL from O-CLL without an increased overall IGHV4-34 gene usage, suggestive of a selective expansion rather than a recombinational bias. Subset #4 cases retained canonical HCDR3 motifs and showed time-to-first-treatment like other M-CLL, likely reflecting the younger age structure of O-CLL1. Conclusions: Early-diagnosis CLL displays a biased IGHV repertoire with stereotyped configurations characteristic of CLL, including subsets that are rare in the normal B-cell repertoire. These findings support a central role for antigen-driven selection in shaping CLL evolution.
EXPLORING THE TRANSCRIPTIONAL PROFILE OF DIS3 CAN UNRAVEL NEW TARGETING STRATEGIES IN MULTIPLE MYELOMA Christian Boni Haematologica, 2026 Introduction. Multiple myeloma (MM) is a rare hematologic malignancy marked by neoplastic transformation of plasma cells (PCs) that are characterized by deep genomic instability. Karyotype abnormalities are considered early events in MM, whereas gene mutations arise later and are related to disease progression. Mutations of DIS3 were found in 10% of MM patients and were preferentially localized within the major ribonuclease (RNB) domain affecting its catalytic activity. In addition, del(13q) found in 40% of MM cases, impact the expression of DIS3. This gene encodes a highly conserved 3′–5′ exoribonuclease associated with the RNA-exosome complex essential for RNA turnover. Here, we characterized the transcriptional landscape induced by DIS3 silencing in an MM cell line and exploited the resultant signature to identify putative synergistic compounds.Methods. DIS3 silencing was performed using LNA-gapmeR designed for gymnosis. Transcriptome profiling by bulk RNA-seq of DIS3-silenced NCI-H929 cells versus gapmeR scrambled as controls was carried out on an Illumina NextSeq 500; DESeq2 pipeline was used for differentially expressed genes analysis. Immunofluorescence experiments were performed using anti α-Tubulin 488-conjugated for mitosis and S9.6 antibody for R-loop detection.Results. Differential expression analysis of RNA-seq identified 809 significantly deregulated genes (FDR<0.05), particularly 492 and 317 genes were found upregulated and downregulated respectively. GO bioprocess analysis of downregulated genes were enriched in microtubule and kinetochore assembly, promoting regulatory role of DIS3 in mitotic spindle organization. Interestingly, upregulated genes were predominantly associated with antiviral immune response and interferon-mediated signaling, a pattern possibly due to RNA accumulation. Additionally, immunofluorescence staining of DIS3 silenced cells showed increased R-Loop formation. To identify synergistic agents consistent with DIS3KD signature, the CMap query analysis revealed a strong association with microtubule-targeting inhibitors. Filanesib (ARRY-520) is a selective kinesin inhibitor of EG5/KIF11 that is fundamental mitotic kinesin necessary for spindle orientation. It has been previously studied for MM therapy—either as monotherapy or in combination—within phase II clinical trials. Filanesib treatment negatively affected cell viability in MM cell lines harboring del(13q) compared to bi-allelic WT counterparts. Furthermore, co-treatment with Filanesib and DIS3 LNA-gapmer produced a synergistic cytostatic response.Conclusions. Our rusults suggest that DIS3KD perturbs mitotic spindle dynamics and fosters genomic instability in MM, consistent with prior evidence that DIS3 depletion increases G0/G1-phase accumulation and compromises centrosome formation. In addition, the synergy observed with a microtubule-targeting agent could encourage future investigation to improve MM treatment strategies.
NONO SHAPES MULTIPLE MYELOMA PROGRESSION THROUGH PARASPECKLE-DEPENDENT AND INDEPENDENT PATHWAYS Elisa Taiana Haematologica, 2026 Introduction: Multiple myeloma (MM) is an incurable cancer caused by malignant proliferation of bone marrow plasma cells. The lncRNA NEAT1, the scaffold of paraspeckle (PS), promotes MM progression by regulating DNA repair and cell survival. NONO, which stabilizes NEAT1 and supports PSs biogenesis, is upregulated in MM and associated with poor survival. In addition to its essential role within PSs, NONO may also have functions beyond PSs. This study aims to define how NONO shapes the transcriptomic landscape of MM plasma cells, both through its PS-associated and independent mechanisms.Methods. RNA was extracted from NONO-KD, NEAT1-KD, and scramble AMO1 and LP1 human MM cells lines (HMCL). RNA-seq libraries were prepared following Illumina Stranded TotalRNA PrepLigation with Ribo-zero Plus protocol (Illumina). Sequencing was performed on Illumina Novaseq 6000 S2 cartridge. CoMMpass data were retrieved from the Interim Analysis 15a (MMRF_CoMMpass_IA15a).Results. To investigate the role of NONO in both PS-related and independent pathways, we compared transcriptomic data from NONO-KD and NEAT1-KD AMO1 and LP1 cells. Overlapping pathways suggested PS-related functions. Silencing NEAT1 or NONO led to significant downregulation of gene sets involved in chromatin modification, as well as WNT/β-catenin and NOTCH signalling pathways. Consistently, RNAseq analysis of NEAT1-overexpressing AMO1 cells revealed positive modulation of the same pathways. Further validation came from GSEA of CoMMpass samples stratified by NONO expression, comparing the two extreme quartiles.Since NONO is essential for protecting NEAT1 from degradation, its silencing results in a marked downregulation of NEAT1 expression levels, thus impacting the transcriptome of NONO-KD cells in a NEAT1-dependent manner. As a result, all the pathways modulated in the NONO-KD HMCLs were also confirmed in the NEAT1-KD samples, making it impossible to identify any pathways regulated by NONO independently of PSs. However, the analysis of data from the extreme quartile of NONO in the CoMMpass dataset identified pathways absent in NEAT1-KD HMCLs, suggesting PS-independent roles for NONO in RNA processing, RNA trafficking, mitochondrial biogenesis, and cell-cell communication. To validate pathways selectively regulated by NONO independently of PS, we focused on its role in intercellular communication and adhesion. Functionally, HUVECs cultured in conditioned media from NONO-KD AMO-1 or NCI-H929 cells showed disrupted VE-cadherin localization and expression, indicating that the NONO-dependent MM secretome can alter endothelial adhesion. These results reveal a potential PS-independent role for NONO in modulating the tumor microenvironment.Conclusions. This study highlights the multifaceted transcriptional roles of NONO in MM, revealing both PS-dependent and -independent functions, and underscores its potential impact on tumor microenvironment regulation and disease progression.
DISSECTION OF NEAT1’S ROLE IN TRANSCRIPTIONAL REGULATION REVEALS ACTIONABLE TARGETS IN HIGH-RISK MULTIPLE MYELOMA Noemi Puccio Haematologica, 2026 Introduction. LncRNAs emerged as a key element of genome regulation, driving multiple myeloma (MM) progression and therapy resistance. Among them, NEAT1 has been described as overexpressed in MM patients, promoting malignant PC proliferation. Besides its conventional function in the assembly of paraspeckles, we recently demonstrated that NEAT1 is directly involved in transcriptional control. In this study, we deepen our understanding of NEAT1’s mechanistic function in shaping the activity of transcriptional bodies, providing the rationale for targeted therapeutic intervention.Methods. We used an RNA-seq approach in NEAT1 KD and in CRISPRa NEAT1 overexpressing AMO-1 cell line to derive a NEAT1 transcriptomic signature. Unsupervised clustering analysis in the CoMMpass dataset was used to validate the clinical relevance of the NEAT1 gene program. Computational approaches were used to predict a list of transcriptional regulators of NEAT1’s signature. RNA immunoprecipitation (RIP) and RNA-FISH combined with immunofluorescence (IF) were used to confirm the in silico prediction in AMO-1 and NCI-H929 cell lines. Chromatin immunoprecipitation (ChIP) was employed to validate the involvement of NEAT1 in the transcriptional apparatus. High-throughput (HT) drug screening in NEAT1 KD cells was used to identify small compounds that interfere with NEAT1-dependent transcriptional activity. Rescue experiments were performed using NEAT1 overexpressing cells.Results. Transcriptomic analysis in NEAT1 KD and in NEAT1 overexpressing AMO-1 cell line revealed 378 NEAT1 targets. Unsupervised clustering analysis based on their expression segregated CoMMpass patients into two distinct groups, displaying high or low NEAT1 transcriptional activity. The cluster with the high NEAT1 transcriptional program showed reduced survival and was enriched in high-risk cytogenetic lesions, including 1q gain/amp and del(17)p. Noticeably, computational analysis predicted FOXM1 and CDK9 as upstream regulators of the NEAT1 program, both components MMB:FOXM1 transcriptional apparatus, which controls the expression of G2/M genes. Consistently, we highlighted that 60% of NEAT1 target genes harbor a Cell cycle homology region (CHR) motif, recognized by MMB:FOXM1 complex. In vitro molecular validation confirmed co-localization of NEAT1 and FOXM1 condensates in MM cells, and direct binding of NEAT1-FOXM1/NEAT1-CDK9. Additionally, we demonstrated that NEAT1 KD results in a reduced occupancy of FOXM1 at the promoters of CHR genes. HT drug screening revealed a synthetic lethal interaction between NEAT1 depletion and CDK9 inhibition, whereas its overexpression confers resistance to CDK9 blockade, confirming the interplay between NEAT1-CDK9 to sustain the mitotic gene program.Conclusions. These findings demonstrate that NEAT1 coordinates the expression of mitotic genes through the interaction with FOXM1 and CDK9, providing a mechanistic rationale for targeted interventions in high-risk patients.
The accuracy of administrative data in identifying pulmonary metastases: a population-based study in Northern Italy Francesco Marinelli, Maria Barbara Braghiroli, Isabella Bisceglia, Francesca Roncaglia, Annamaria Pezzarossi, Fortunato Morabito, Antonino Neri, Paolo Giorgi Rossi, Lucia Mangone European Journal of Cancer Prevention, 2026 Objective Lung cancer remains a highly prevalent and lethal disease, with the majority of tumors identified at advanced stages. Screening with low-dose CT was shown to be effective in reducing mortality through early diagnosis. Administrative data are increasingly utilized in clinical settings and research for identifying metastatic lung cancer, yet their accuracy and limitations require thorough evaluation. Methods This study evaluated the use of administrative data to identify lung cancer metastases within the population-based cancer registry (CR) of Reggio Emilia by cross-referencing registry data with administrative hospital discharge records (HDRs). Distant metastases were identified using specific International Classification of Diseases, 9th revision codes, with medical records reviewed to validate and refine the identification process. Standardized incidence and mortality rates were calculated and analyzed using joinpoint regression. Results Between 2018 and 2021, 1391 lung cancers exhibiting at least one HDR were identified. Of these, 383 (27.5%) cases had distant metastases, 80 (6%) had a second tumor, and 12 (1.5%) had unknown tumor sites. After a manual review of cases with codes 196 (secondary and unspecified malignant neoplasm of lymph nodes) and code 199 (malignant neoplasm without specification of the site), the number of identified metastatic tumors increased to 30.5%. Lung cancer metastases identified by the CR showed an HDR sensitivity equal to 32.6%. Conclusion Administrative data, even with manual verification, achieved a positive predictive value of 30.5 for metastatic tumors. The scientific community and policymakers must be aware of these limitations and the need for additional resources to accurately screen to evaluate lung cancer.
To Treat or Not to Treat: Navigating Early-Stage CLL in the Era of Targeted Therapy Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Giovanna Cutrona, Antonella Bruzzese, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Franco Fais, Antonino Neri, Manlio Ferrarini, Valter Gattei, Fortunato Morabito, Massimo Gentile European Journal of Haematology, 2026
Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions Caterina Labanca, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Noemi Puccio, Antonino Neri, Fortunato Morabito, Massimo Gentile European Journal of Haematology, 2025
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study Enrica Antonia Martino, Daniele Derudas, Elena Rossi, Paola Stefanoni, Silvia Mangiacavalli, Elena Zamagni, Massimo Offidani, Anna Furlan, Angela Maria Quinto, Roberta Della Pepa, Giuseppe Bertuglia, Emiliano Barbieri, Concetta Conticello, Claudio De Magistris, Velia Bongarzoni, Anna Maria Cafro, Anna Mele, Cirino Botta, Nicola Sgherza, Giuseppe Mele, Ombretta Annibali, Angela Rago, Raffaele Fontana, Ernesto Vigna, Antonella Bruzzese, Katia Mancuso, Angela Amendola, Annalisa Citro, Emilia Cotzia, Sonia Morè, Elena Rivolti, Loredana Pettine, Monica Galli, Valerio De Stefano, Maria Teresa Petrucci, Alessandro Corso, Antonino Neri, Francesco Di Raimondo, Niccolò Bolli, Pellegrino Musto, Fortunato Morabito, Massimo Gentile Hematological Oncology, 2025
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients E.A. Martino, S. Palmieri, M. Galli, D. Derudas, R. Mina, R. Della Pepa, R. Zambello, E. Vigna, A. Bruzzese, S. Mangiacavalli, E. Zamagni, C. Califano, M. Musso, C. Conticello, C. Cerchione, G. Mele, N. Di Renzo, M. Offidani, G. Tarantini, G.M. Casaluci, A. Rago, R. Ria, G. Uccello, G. Barilà, G. Palumbo, L. Pettine, C. De Magistris, I.D. Vincelli, M. Brunori, F. Accardi, V. Amico, A. Amendola, R. Fontana, V. Bongarzoni, B. Rossini, E. Cotzia, A. Gozzetti, R. Rizzi, N. Sgherza, P. Curci, K. Mancuso, G. Reddiconto, A. Maroccia, L. Franceschini, G. Bertuglia, D. Nappi, E. Barbieri, M. Quaresima, M.T. Petrucci, F. Di Raimondo, A. Neri, G. Tripepi, P. Musto, F. Morabito, M. Gentile ESMO Open, 2025
Therapy-Related Acute Promyelocytic Leukemia: Case Series and Current Insights Antonella Bruzzese, Enrica Antonia Martino, Caterina Labanca, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Rosellina Morelli, Teresa Rossi, Antonino Neri, Fortunato Morabito, Massimo Gentile, Ernesto Vigna European Journal of Haematology, 2025
Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study Alberto Bavieri, Maria E. Nizzoli, Alessandra Tucci, Vittorio R. Zilioli, Jacopo Olivieri, Benedetta Bianchi, Mansueto G. Rosaria, Ombretta Annibali, Alessia Bari, Gloria M. Casaluci, Michele Cimminiello, Nicola Di Renzo, Federica Cavallo, Vicenzo Pavone, Clara Mannarella, Annalisa Arcari, Maggi Alessandro, Antonella Anastasia, Vittoria Tarantino, Antonino Neri, Massimo Gentile, Fortunato Morabito, Stefano Luminari Hemasphere, 2024
Programmed Death Ligand 1 (PD-L1) Expression in Lymphomas: State of the Art Magda Zanelli, Valentina Fragliasso, Paola Parente, Alessandra Bisagni, Francesca Sanguedolce, Maurizio Zizzo, Giuseppe Broggi, Stefano Ricci, Andrea Palicelli, Moira Foroni, Fabrizio Gozzi, Pietro Gentile, Andrea Morini, Nektarios Koufopoulos, Rosario Caltabiano, Luca Cimino, Massimiliano Fabozzi, Alberto Cavazza, Antonino Neri, Stefano Ascani International Journal of Molecular Sciences, 2024
Teclistamab-cqyv in multiple myeloma Enrica Antonia Martino, Antonella Bruzzese, Caterina Labanca, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Antonino Neri, Fortunato Morabito, Ernesto Vigna, Massimo Gentile European Journal of Haematology, 2024
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort Enrica Antonia Martino, Francesca Romana Mauro, Gianluigi Reda, Luca Laurenti, Andrea Visentin, Annamaria Frustaci, Ernesto Vigna, Sara Pepe, Gioacchino Catania, Giacomo Loseto, Roberta Murru, Annalisa Chiarenza, Paolo Sportoletti, Maria Ilaria Del Principe, Roberta Laureana, Marta Coscia, Sara Galimberti, Eleonora Ferretti, Antonella Zucchetto, Riccardo Bomben, Jerry Polesel, Alessandra Tedeschi, Davide Rossi, Livio Trentin, Antonino Neri, Fortunato Morabito, Valter Gattei, Massimo Gentile Hematological Oncology, 2024
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials Massimo Gentile, Ernesto Vigna, Salvatore Palmieri, Monica Galli, Daniele Derudas, Roberto Mina, Roberta Della Pepa, Renato Zambello, Enrica Antonia Martino, Antonella Bruzzese, Silvia Mangiacavalli, Elena Zamagni, Catello Califano, Maurizio Musso, Concetta Conticello, Claudio Cerchione, Giuseppe Mele, Nicola Di Renzo, Massimo Offidani, Giuseppe Tarantini, Gloria Margiotta Casaluci, Angela Rago, Roberto Ria, Giuseppina Uccello, Gregorio Barilà, Gaetano Palumbo, Alessandra Pompa, Donatella Vincelli, Marino Brunori, Fabrizio Accardi, Valeria Amico, Angela Amendola, Raffaele Fontana, Velia Bongarzoni, Bernardo Rossini, Emilia Cotzia, Alessandro Gozzetti, Rita Rizzi, Nicola Sgherza, Eleonora Ferretti, Giuseppe Bertuglia, Davide Nappi, Maria Teresa Petrucci, Francesco Di Raimondo, Antonino Neri, Fortunato Morabito, Pellegrino Musto Haematologica, 2024
Myelodysplastic syndromes with ring sideroblasts Antonella Bruzzese, Ernesto Vigna, Enrica Antonia Martino, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Carlo Bova, Angelo Barbato, Gianfranco Filippelli, Isabella Capodanno, Antonino Neri, Fortunato Morabito, Massimo Gentile Hematological Oncology, 2023
The Potential of JAG Ligands as Therapeutic Targets and Predictive Biomarkers in Multiple Myeloma Natalia Platonova, Elisa Lazzari, Michela Colombo, Monica Falleni, Delfina Tosi, Domenica Giannandrea, Valentina Citro, Lavinia Casati, Domenica Ronchetti, Niccolò Bolli, Antonino Neri, Federica Torricelli, Leslie A. Crews, Catriona H. M. Jamieson, Raffaella Chiaramonte International Journal of Molecular Sciences, 2023
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 – VERITAS study Francesca R. Mauro, Irene Della Starza, Monica Messina, Gianluigi Reda, Livio Trentin, Marta Coscia, Paolo Sportoletti, Lorella Orsucci, Valentina Arena, Gloria Margiotta Casaluci, Roberto Marasca, Roberta Murru, Luca Laurenti, Fiorella Ilariucci, Caterina Stelitano, Donato Mannina, Massimo Massaia, Gian Matteo Rigolin, Lydia Scarfò, Monia Marchetti, Luciano Levato, Monica Tani, Annalisa Arcari, Gerardo Musuraca, Marina Deodato, Piero Galieni, Valeria Belsito Patrizi, Daniela Gottardi, Anna Marina Liberati, Annamaria Giordano, Maria Chiara Molinari, Daniela Pietrasanta, Veronica Mattiello, Andrea Visentin, Candida Vitale, Francesco Albano, Antonino Neri, Lucia Anna De Novi, Maria Stefania De Propris, Mauro Nanni, Ilaria Del Giudice, Anna Guarini, Paola Fazi, Marco Vignetti, Alfonso Piciocchi, Antonio Cuneo, Robin Foà Haematologica, 2023
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia Fortunato Morabito, Giovanni Tripepi, Francesca Romana Mauro, Luca Laurenti, Gianluigi Reda, Riccardo Moia, Adalgisa Condoluci, Iolanda Vincelli, Annalisa Chiarenza, Ernesto Vigna, Enrica Antonia Martino, Antonella Bruzzese, Sabrina Mezzatesta, Roberta Laureana, Giovanna Cutrona, Francesco Di Raimondo, Gilberto Fronza, Antonella Zucchetto, Riccardo Bomben, Francesca Maria Rossi, Jacopo Olivieri, Francesco Zaja, Davide Rossi, Gianluca Gaidano, Maria Ilaria Del Principe, Fiorella Ilariucci, Giovanni Del Poeta, Manlio Ferrarini, Antonino Neri, Valter Gattei, Massimo Gentile American Journal of Hematology, 2023
Ibrutinib in patients over 80 years old with CLL: a multicenter Italian cohort Gianluigi Reda, Veronica Mattiello, Anna Maria Frustaci, Andrea Visentin, Francesca Romana Mauro, Idanna Innocenti, Massimo Gentile, Diana Giannarelli, Alessandro Noto, Ramona Cassin, Antonino Neri, Luca Laurenti, Alessandra Tedeschi Blood Advances, 2023
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents Pamela Becherini, Debora Soncini, Silvia Ravera, Elisa Gelli, Claudia Martinuzzi, Giulia Giorgetti, Antonia Cagnetta, Fabio Guolo, Federico Ivaldi, Maurizio Miglino, Sara Aquino, Katia Todoerti, Antonino Neri, Andrea Benzi, Mario Passalacqua, Alessio Nencioni, Ida Perrotta, Maria Eugenia Gallo Cantafio, Nicola Amodio, Antonio De Flora, Santina Bruzzone, Roberto M. Lemoli, Michele Cea Antioxidants, 2023
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “Real-World” study Shai Levi, Yotam Bronstein, Neta Goldschmidt, Fortunato Morabito, Tomer Ziv‐Baran, Giovanni Del Poeta, Osnat Bairey, Maria Ilaria Del Principe, Riva Fineman, Francesca Romana Mauro, Odit Gutwein, Gianluigi Reda, Rosa Ruchlemer, Paolo Sportoletti, Luca Laurenti, Lev Shvidel, Marta Coscia, Tamar Tadmor, Marzia Varettoni, Ariel Aviv, Roberta Murru, Andrei Braester, Annalisa Chiarenza, Andrea Visentin, Daniela Pietrasanta, Giacomo Loseto, Antonella Zucchetto, Riccardo Bomben, Jacopo Olivieri, Antonio Neri, Davide Rossi, Gianluca Gaidano, Livio Trentin, Robin Foà, Antonio Cuneo, Chava Perry, Valter Gattei, Massimo Gentile, Yair Herishanu American Journal of Hematology, 2023
A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth Eugenio Morelli, Mariateresa Fulciniti, Mehmet K. Samur, Caroline Ribeiro, Leon Wert-Lamas, Jonathan E Henninger, Annamaria Gulla, Anil Aktas Samur, Katia Todoerti, Srikanth Talluri, Woojun D. Park, Cinzia Federico, Francesca Scionti, Nicola Amodio, Giada Bianchi, Megan Johnstone, Na Liu, Doriana Gramegna, Domenico Maisano, Nicola A Russo, Charles Y. Lin, Yu-Tzu Tai, Antonino Neri, Dharminder Chauhan, Teru Hideshima, Masood A Shammas, Pierfrancesco Tassone, Sergei Gryaznov, Richard Young, Kenneth C. Anderson, Carl D. Novina, Massimo Loda, Nikhil C. Munshi Blood, 2023
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia Eugenio Morelli, Zachary R. Hunter, Mariateresa Fulciniti, Annamaria Gullà, Ida Daniela Perrotta, Valeria Zuccalà, Cinzia Federico, Giada Juli, Martina Manzoni, Domenica Ronchetti, Enrica Romeo, Maria Eugenia Gallo Cantafio, Debora Soncini, Lorenza Maltese, Marco Rossi, Aldo M. Roccaro, Michele Cea, Pierfrancesco Tassone, Antonino Neri, Steven C. Treon, Nikhil C. Munshi, Giuseppe Viglietto, Nicola Amodio Experimental Hematology and Oncology, 2022
Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity Carmine Rocca, Ernestina Marianna De Francesco, Teresa Pasqua, Maria Concetta Granieri, Anna De Bartolo, Maria Eugenia Gallo Cantafio, Maria Grazia Muoio, Massimo Gentile, Antonino Neri, Tommaso Angelone, Giuseppe Viglietto, Nicola Amodio Biomedicines, 2022
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients Fortunato Morabito, Elena Zamagni, Concetta Conticello, Vincenzo Pavone, Salvatore Palmieri, Sara Bringhen, Monica Galli, Silvia Mangiacavalli, Daniele Derudas, Elena Rossi, Roberto Ria, Lucio Catalano, Paola Tacchetti, Giuseppe Mele, Iolanda Donatella Vincelli, Enrica Antonia Martino, Ernesto Vigna, Cirino Botta, Antonella Bruzzese, Anna Mele, Lucia Pantani, Serena Rocchi, Bruno Garibaldi, Nicola Cascavilla, Stelvio Ballanti, Giovanni Tripepi, Ferdinando Frigeri, Antonetta Pia Falcone, Clotilde Cangialosi, Giovanni Reddiconto, Giuliana Farina, Marialucia Barone, Ilaria Rizzello, Pellegrino Musto, Valerio De Stefano, Maurizio Musso, Maria Teresa Petrucci, Massimo Offidani, Antonino Neri, Nicola Di Renzo, Francesco Di Raimondo, Mario Boccadoro, Michele Cavo, Massimo Gentile, Catello Califano, Nicola Giuliani, Enrico Attingenti, Alessandra Lombardo, Elisabetta Antonioli, Gianpaolo Marcacci, Valeria Amico, Silvana Capalbo, Claudio Cerchione, Angelo Belotti, Clelia Criscuolo, Angela Bonalumi, Agostina Siniscalchi, Francesca Patriarca, Raffaella Stocchi, Massimo Martino, Dominella Gangemi, Alfredo Gagliardi, Barbara Gamberi, Micol Quaresma, Alessandra Pompa, Ugo Consoli, Giuseppina Uccello, Gregorio Barilà, Elisabetta Antonioli, Michela Staderini, Gabriele Buda, Mario Petrini, Anna Furlan, Angela Bonalumi, Giulia Palazzo, Sabrina Sabatelli, Patrizio Mazza, Candida Germano, Rosanna Miccolis, Giuseppe Tarantini, Gaetano Palumbo, Attilio Guarini, Emilia Cotzia, Vanessa Innao, Donato Mannina, Santo Neri, Giovanni Cardinale, Anxur Merenda, Cinzia Maugeri, Massimo Poidomani, Giuseppe Longo, Melania Carlisi, Gino Svanera, Antonello Sica, Daniela Esposito, Raffaele Fontana, Valerio Amico, Adelina Sementa European Journal of Haematology, 2022
LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells Serena Matis, Martina Rossi, Lorenzo Brondolo, Martina Cardillo, Daniele Reverberi, Rosanna Massara, Monica Colombo, Adalberto Ibatici, Emanuele Angelucci, Tiziana Vaisitti, Silvia Bruno, Sonia Fabris, Antonino Neri, Massimo Gentile, Fortunato Morabito, Giovanna Cutrona, Paola Briata, Roberto Gherzi, Franco Fais Hematological Oncology, 2022
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study Francesca Romana Mauro, Francesca Paoloni, Stefano Molica, Gianluigi Reda, Livio Trentin, Paolo Sportoletti, Monia Marchetti, Daniela Pietrasanta, Roberto Marasca, Gianluca Gaidano, Marta Coscia, Caterina Stelitano, Donato Mannina, Nicola Di Renzo, Fiorella Ilariucci, Anna Marina Liberati, Lorella Orsucci, Francesca Re, Monica Tani, Gerardo Musuraca, Daniela Gottardi, Pier Luigi Zinzani, Alessandro Gozzetti, Annalia Molinari, Massimo Gentile, Annalisa Chiarenza, Luca Laurenti, Marzia Varettoni, Adalberto Ibatici, Roberta Murru, Valeria Ruocco, Ilaria Del Giudice, Maria Stefania De Propris, Irene Della Starza, Sara Raponi, Mauro Nanni, Paola Fazi, Antonino Neri, Anna Guarini, Gian Matteo Rigolin, Alfonso Piciocchi, Antonio Cuneo, Robin Foà Cancers, 2022
Functional impact of genomic complexity on the transcriptome of multiple myeloma Bachisio Ziccheddu, Matteo C. Da Vià, Marta Lionetti, Akihiro Maeda, Silvia Morlupi, Matteo Dugo, Katia Todoerti, Stefania Oliva, Mattia D'Agostino, Paolo Corradini, Ola Landgren, Francesco Iorio, Loredana Pettine, Alessandra Pompa, Martina Manzoni, Luca Baldini, Antonino Neri, Francesco Maura, Niccolò Bolli Clinical Cancer Research, 2021
Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity Antonio Sacco, Cinzia Federico, Katia Todoerti, Bachisio Ziccheddu, Valentina Palermo, Arianna Giacomini, Cosetta Ravelli, Federica Maccarinelli, Giada Bianchi, Angelo Belotti, Rossella Ribolla, Vanessa Favasuli, Alexey S. Revenko, A. Robert Macleod, Brandon Willis, Hongbo Cai, Joana Hauser, Claire Rooney, Sophie E. Willis, Philip Lloyd Martin, Anna Staniszewska, Helen Ambrose, Lyndsey Hanson, Chiara Cattaneo, Alessandra Tucci, Giuseppe Rossi, Roberto Ronca, Antonino Neri, Stefania Mitola, Niccolò Bolli, Marco Presta, Michele Moschetta, Sarah Ross, Aldo M. Roccaro Blood, 2021
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia Fortunato Morabito, Giovanni Tripepi, Riccardo Moia, Anna Grazia Recchia, Paola Boggione, Francesca Romana Mauro, Sabrina Bossio, Graziella D’Arrigo, Enrica Antonia Martino, Ernesto Vigna, Francesca Storino, Gilberto Fronza, Francesco Di Raimondo, Davide Rossi, Adalgisa Condoluci, Monica Colombo, Franco Fais, Sonia Fabris, Robin Foa, Giovanna Cutrona, Massimo Gentile, Emili Montserrat, Gianluca Gaidano, Manlio Ferrarini, Antonino Neri Frontiers in Oncology, 2021
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials Fortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Paolo Sportoletti, Luca Laurenti, Marta Coscia, Yair Herishanu, Sabrina Bossio, Marzia Varettoni, Roberta Murru, Annalisa Chiarenza, Andrea Visentin, Adalgisa Condoluci, Riccardo Moia, Daniela Pietrasanta, Giacomo Loseto, Ugo Consoli, Ilaria Scortechini, Francesca Maria Rossi, Antonella Zucchetto, Hamdi Al‐Janazreh, Ernesto Vigna, Enrica Antonia Martino, Ramona Cassin, Graziella D′Arrigo, Sara Galimberti, Angela Rago, Ilaria Angeletti, Annalisa Biagi, Ilaria Del Giudice, Riccardo Bomben, Antonino Neri, Gilberto Fronza, Paola Monti, Paola Menichini, Jacopo Olivieri, Giovanna Cutrona, Davide Rossi, Antonio Cuneo, Francesco Di Raimondo, Gianluca Gaidano, Aaron Polliack, Livio Trentin, Robin Foà, Manlio Ferrarini, Valter Gattei, Massimo Gentile American Journal of Hematology, 2021
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases Fortunato Morabito, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Paolo Sportoletti, Luca Laurenti, Marta Coscia, Yair Herishanu, Sabrina Bossio, Marzia Varettoni, Roberta Murru, Annalisa Chiarenza, Andrea Visentin, Adalgisa Condoluci, Riccardo Moia, Daniela Pietrasanta, Giacomo Loseto, Ugo Consoli, Ilaria Scortechini, Anna Grazia Recchia, Francesca Maria Rossi, Antonella Zucchetto, Hamdi Al‐Janazreh, Enrica Antonia Martino, Ernesto Vigna, Giovanni Tripepi, Graziella D'Arrigo, Sara Galimberti, Angela Rago, Ilaria Angeletti, Annalisa Biagi, Ilaria Del Giudice, Riccardo Bomben, Antonino Neri, Gilberto Fronza, Giovanna Cutrona, Ozren Jaksic, Jacopo Olivieri, Davide Rossi, Francesco Di Raimondo, Antonio Cuneo, Gianluca Gaidano, Aaron Polliack, Livio Trentin, Robin Foà, Manlio Ferrarini, Valter Gattei, Massimo Gentile American Journal of Hematology, 2021
What is new in the treatment of smoldering multiple myeloma? Niccolo’ Bolli, Nicola Sgherza, Paola Curci, Rita Rizzi, Vanda Strafella, Mario Delia, Vito Pier Gagliardi, Antonino Neri, Luca Baldini, Francesco Albano, Pellegrino Musto Journal of Clinical Medicine, 2021
In Vitro Silencing of lncRNAs Using LNA GapmeRs Elisa Taiana, Vanessa Favasuli, Domenica Ronchetti, Eugenio Morelli, Pierfrancesco Tassone, Giuseppe Viglietto, Nikhil C. Munshi, Antonino Neri, Nicola Amodio Methods in Molecular Biology, 2021
Spotlight on melphalan flufenamide: An up-and-coming therapy for the treatment of myeloma Fortunato Morabito, Giovanni Tripepi, Enrica Antonia Martino, Ernesto Vigna, Francesco Mendicino, Lucio Morabito, Katia Todoerti, Hamdi Al-Janazreh, Graziella D’Arrigo, Filippo Antonio Canale, Giovanna Cutrona, Antonino Neri, Massimo Martino, Massimo Gentile Drug Design Development and Therapy, 2021
Ensuring continuity of care of hematologic patients during COVID-19 pandemic in a tertiary hospital in Lombardy (Italy) Bruno Fattizzo, Juri Alessandro Giannotta, Wilma Barcellini, Maria Chiara Barbanti, Cristina Bucelli, Ramona Cassin, Daniele Cattaneo, Francesca Cavallaro, Valeria Ferla, Nicola Stefano Fracchiolla, Alessandra Freyrie, Giulia Galassi, Maria Cecilia Goldaniga, Federica Irene Grifoni, Alessandra Iurlo, Giancarlo Mangiameli, Veronica Mattiello, Mario Meli, Antonino Neri, Alessandro Noto, Francesco Onida, Laura Ottani, Raffaella Pasquale, Loredana Pettine, Alessandra Pompa, Gianluigi Reda, Francesca Gaia Rossi, Giorgia Natascia Saporiti, Mariarita Sciumè, Elena Tagliaferri, Luca Baldini Blood Advances, 2020
Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance Michela Colombo, Silvia Garavelli, Mara Mazzola, Natalia Platonova, Domenica Giannandrea, Raffaella Colella, Luana Apicella, Marialuigia Lancellotti, Elena Lesma, Silvia Ancona, Maria Teresa Palano, Marzia Barbieri, Elisa Taiana, Elisa Lazzari, Andrea Basile, Mauro Turrini, Anna Pistocchi, Antonino Neri, Raffaella Chiaramonte Haematologica, 2020
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia Jared A. Cohen, Francesca Maria Rossi, Antonella Zucchetto, Riccardo Bomben, Lodovico Terzi-di-Bergamo, Kari G. Rabe, Massimo Degan, Agostino Steffan, Jerry Polesel, Enrico Santinelli, Idanna Innocenti, Giovanna Cutrona, Giovanni D’Arena, Gabriele Pozzato, Francesco Zaja, Annalisa Chiarenza, Davide Rossi, Francesco Di Raimondo, Luca Laurenti, Massimo Gentile, Fortunato Morabito, Antonino Neri, Manlio Ferrarini, Christopher D. Fegan, Christopher J. Pepper, Giovanni Del Poeta, Sameer A. Parikh, Neil E. Kay, Valter Gattei Haematologica, 2020
International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia Adalgisa Condoluci, Lodovico Terzi di Bergamo, Petra Langerbeins, Manuela A. Hoechstetter, Carmen D. Herling, Lorenzo De Paoli, Julio Delgado, Kari G. Rabe, Massimo Gentile, Michael Doubek, Francesca R. Mauro, Giorgia Chiodin, Mattias Mattsson, Jasmin Bahlo, Giovanna Cutrona, Jana Kotaskova, Clara Deambrogi, Karin E. Smedby, Valeria Spina, Alessio Bruscaggin, Wei Wu, Riccardo Moia, Elena Bianchi, Bernhard Gerber, Emanuele Zucca, Silke Gillessen, Michele Ghielmini, Franco Cavalli, Georg Stussi, Mark A. Hess, Tycho S. Baumann, Antonino Neri, Manlio Ferrarini, Richard Rosenquist, Francesco Forconi, Robin Foà, Sarka Pospisilova, Fortunato Morabito, Stephan Stilgenbauer, Hartmut Döhner, Sameer A. Parikh, William G. Wierda, Emili Montserrat, Gianluca Gaidano, Michael Hallek, Davide Rossi Blood, 2020
Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma Francesco Maura, Luca Agnelli, Daniel Leongamornlert, Niccolò Bolli, Wing C. Chan, Anna Dodero, Cristiana Carniti, Tayla B. Heavican, Alessio Pellegrinelli, Giancarlo Pruneri, Adam Butler, Shriram G. Bhosle, Annalisa Chiappella, Alice Di Rocco, Pier Luigi Zinzani, Francesco Zaja, Roberto Piva, Giorgio Inghirami, Wenyi Wang, Teresa Palomero, Javeed Iqbal, Antonino Neri, Peter J. Campbell, Paolo Corradini American Journal of Hematology, 2019
Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment Massimo Gentile, Tait D. Shanafelt, Francesca Romana Mauro, Gianluigi Reda, Davide Rossi, Luca Laurenti, Maria Ilaria Del Principe, Giovanna Cutrona, Ilaria Angeletti, Marta Coscia, Yair Herishanu, Annalisa Chiarenza, Stefano Molica, Stefania Ciolli, Neta Goldschmidt, Francesco Angrilli, Annamaria Giordano, Angela Rago, Osnat Bairey, Giovanni Tripepi, Kari G. Chaffee, Parikh A. Sameer, Ernesto Vigna, Katja Zirlik, Lev Shvidel, Idanna Innocenti, Anna Grazia Recchia, Francesco Di Raimondo, Giovanni Del Poeta, Agostino Cortelezzi, Antonino Neri, Manlio Ferrarini, Gianluca Gaidano, Neil E. Kay, Aaron Polliack, Robin Foà, Fortunato Morabito European Journal of Haematology, 2018
Global methylation patterns in primary plasma cell leukemia Katia Todoerti, Giovanni Calice, Stefania Trino, Vittorio Simeon, Marta Lionetti, Martina Manzoni, Sonia Fabris, Marzia Barbieri, Alessandra Pompa, Luca Baldini, Valentina Bollati, Pietro Zoppoli, Antonino Neri, Pellegrino Musto Leukemia Research, 2018
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 Eugenio Morelli, Lavinia Biamonte, Cinzia Federico, Nicola Amodio, Maria Teresa Di Martino, Maria Eugenia Gallo Cantafio, Martina Manzoni, Francesca Scionti, Mehmet Kemal Samur, Annamaria Gullà, Maria Angelica Stamato, Maria Rita Pitari, Daniele Caracciolo, Settimio Sesti, Niels M. Frandsen, Marco Rossi, Antonino Neri, Mariateresa Fulciniti, Nikhil C. Munshi, Pierosandro Tagliaferri, Pierfrancesco Tassone Blood, 2018
Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab Massimo Gentile, Tait D. Shanafelt, Gianluigi Reda, Francesca Romana Mauro, Katja Zirlik, Stefania Ciolli, Luca Laurenti, Maria Ilaria Del Principe, Davide Rossi, Nicola Di Renzo, Stefano Molica, Francesco Angrilli, Marta Coscia, Annalisa Chiarenza, Annamaria Giordano, Giovanna Cutrona, Kari G. Chaffee, Sameer A. Parikh, Giuseppina Uccello, Idanna Innocenti, Giovanni Tripepi, Graziella D’Arrigo, Ernesto Vigna, Anna Grazia Recchia, Yair Herishanu, Lev Shvidel, Tamar Tadmor, Agostino Cortelezzi, Giovanni Del Poeta, Gianluca Gaidano, Francesco Di Raimondo, Antonino Neri, Manlio Ferrarini, Robin Foà, Aaron Polliack, Fortunato Morabito Leukemia, 2018
Pathogenicity of InVivo generated intestinal Th17 lymphocytes is IFNγ dependent Giulia Nizzoli, Claudia Burrello, Fulvia Milena Cribiù, Giulia Lovati, Giulia Ercoli, Fiorenzo Botti, Elena Trombetta, Laura Porretti, Katia Todoerti, Antonino Neri, Maria Rita Giuffrè, Jens Geginat, Maurizio Vecchi, Maria Rescigno, Moira Paroni, Flavio Caprioli, Federica Facciotti Journal of Crohn S and Colitis, 2018
Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias Bernhard Gerber, Martina Manzoni, Valeria Spina, Alessio Bruscaggin, Marta Lionetti, Sonia Fabris, Marzia Barbieri, Gabriella Ciceri, Alessandra Pompa, Gabriela Forestieri, Erika Lerch, Paolo Servida, Francesco Bertoni, Emanuele Zucca, Michele Ghielmini, Agostino Cortelezzi, Franco Cavalli, Georg Stussi, Luca Baldini, Davide Rossi, Antonino Neri Haematologica, 2018
Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma Valeria Spina, Alessio Bruscaggin, Annarosa Cuccaro, Maurizio Martini, Martina Di Trani, Gabriela Forestieri, Martina Manzoni, Adalgisa Condoluci, Alberto Arribas, Lodovico Terzi-Di-Bergamo, Silvia Laura Locatelli, Elisa Cupelli, Luca Ceriani, Alden A. Moccia, Anastasios Stathis, Luca Nassi, Clara Deambrogi, Fary Diop, Francesca Guidetti, Alessandra Cocomazzi, Salvatore Annunziata, Vittoria Rufini, Alessandro Giordano, Antonino Neri, Renzo Boldorini, Bernhard Gerber, Francesco Bertoni, Michele Ghielmini, Georg Stüssi, Armando Santoro, Franco Cavalli, Emanuele Zucca, Luigi Maria Larocca, Gianluca Gaidano, Stefan Hohaus, Carmelo Carlo-Stella, Davide Rossi Blood, 2018
Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases Massimo Gentile, Tait D. Shanafelt, Francesca R. Mauro, Luca Laurenti, Davide Rossi, Stefano Molica, Iolanda Vincelli, Giovanna Cutrona, Giuseppina Uccello, Sara Pepe, Ernesto Vigna, Giovanni Tripepi, Kari G. Chaffee, Sameer A. Parikh, Sabrina Bossio, Anna Grazia Recchia, Idanna Innocenti, Raffaella Pasquale, Antonino Neri, Manlio Ferrarini, Gianluca Gaidano, Robin Foà, Fortunato Morabito American Journal of Hematology, 2018
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells’ vulnerability to DNA-damaging agents Antonia Cagnetta, Debora Soncini, Stefania Orecchioni, Giovanna Talarico, Paola Minetto, Fabio Guolo, Veronica Retali, Nicoletta Colombo, Enrico Carminati, Marino Clavio, Maurizio Miglino, Micaela Bergamaschi, Aimable Nahimana, Michel Duchosal, Katia Todoerti, Antonino Neri, Mario Passalacqua, Santina Bruzzone, Alessio Nencioni, Francesco Bertolini, Marco Gobbi, Roberto M. Lemoli, Michele Cea Haematologica, 2018
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma Matteo Marchesini, Yamini Ogoti, Elena Fiorini, Anil Aktas Samur, Luigi Nezi, Marianna D'Anca, Paola Storti, Mehmet Kemal Samur, Irene Ganan-Gomez, Maria Teresa Fulciniti, Nipun Mistry, Shan Jiang, Naran Bao, Valentina Marchica, Antonino Neri, Carlos Bueso-Ramos, Chang-Jiun Wu, Li Zhang, Han Liang, Xinxin Peng, Nicola Giuliani, Giulio Draetta, Karen Clise-Dwyer, Hagop Kantarjian, Nikhil Munshi, Robert Orlowski, Guillermo Garcia-Manero, Ronald A. DePinho, Simona Colla Cancer Cell, 2017
Combining anti-miR-155 with chemotherapy for the treatment of lung cancers Katrien Van Roosbroeck, Francesca Fanini, Tetsuro Setoyama, Cristina Ivan, Cristian Rodriguez-Aguayo, Enrique Fuentes-Mattei, Lianchun Xiao, Ivan Vannini, Roxana S. Redis, Lucilla D'Abundo, Xinna Zhang, Milena S. Nicoloso, Simona Rossi, Vianey Gonzalez-Villasana, Rajesha Rupaimoole, Manuela Ferracin, Fortunato Morabito, Antonino Neri, Peter P. Ruvolo, Vivian R. Ruvolo, Chad V. Pecot, Dino Amadori, Lynne Abruzzo, Steliana Calin, Xuemei Wang, M. James You, Alessandra Ferrajoli, Robert Orlowski, William Plunkett, Tara M. Lichtenberg, Ramana V. Davuluri, Ioana Berindan-Neagoe, Massimo Negrini, Ignacio I. Wistuba, Hagop M. Kantarjian, Anil K. Sood, Gabriel Lopez-Berestein, Michael J. Keating, Muller Fabbri, George A. Calin Clinical Cancer Research, 2017
Targeting notch as a therapeutic approach for human malignancies Natalia Platonova, Elena Lesma, Andrea Basile, Monica Bignotto, Silvia Garavelli, Maria Teresa Palano, Adriana Moschini, Antonino Neri, Michela Colombo, Raffaella Chiaramonte Current Pharmaceutical Design, 2017
Clonal evolution in therapy-related neoplasms Emiliano Fabiani, Giulia Falconi, Luana Fianchi, Marianna Criscuolo, Tiziana Ottone, Laura Cicconi, Stefan Hohaus, Simona Sica, Massimiliano Postorino, Antonino Neri, Marta Lionetti, Giuseppe Leone, Francesco Lo-Coco, Maria Teresa Voso Oncotarget, 2017
Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients Massimo Gentile, Tait D. Shanafelt, Davide Rossi, Luca Laurenti, Francesca R. Mauro, Stefano Molica, Giovanna Cutrona, Giuseppina Uccello, Melissa Campanelli, Ernesto Vigna, Giovanni Tripepi, Kari G. Chaffee, Sameer A. Parikh, Sabrina Bossio, Anna Grazia Recchia, Idanna Innocenti, Raffaella Pasquale, Antonino Neri, Manlio Ferrarini, Gianluca Gaidano, Robin Foà, Fortunato Morabito Blood, 2016
Compendium of FAM46C gene mutations in plasma cell dyscrasias Marzia Barbieri, Martina Manzoni, Sonia Fabris, Gabriella Ciceri, Katia Todoerti, Vittorio Simeon, Pellegrino Musto, Agostino Cortelezzi, Luca Baldini, Antonino Neri, Marta Lionetti British Journal of Haematology, 2016
Therapeutic targeting of miR-29b/HDAC4 epigenetic loop in multiple myeloma Nicola Amodio, Maria Angelica Stamato, Anna Maria Gullà, Eugenio Morelli, Enrica Romeo, Lavinia Raimondi, Maria Rita Pitari, Ida Ferrandino, Gabriella Misso, Michele Caraglia, Ida Perrotta, Antonino Neri, Mariateresa Fulciniti, Christian Rolfo, Kenneth C. Anderson, Nikhil C. Munshi, Pierosandro Tagliaferri, Pierfrancesco Tassone Molecular Cancer Therapeutics, 2016
A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients M Gentile, T D Shanafelt, G Cutrona, S Molica, G Tripepi, I Alvarez, F R Mauro, N Di Renzo, F Di Raimondo, I Vincelli, K Todoerti, S Matis, C Musolino, S Fabris, E Vigna, L Levato, S Zupo, F Angrilli, U Consoli, G Festini, G Longo, A Cortelezzi, A Arcari, M Federico, D Mannina, A G Recchia, A Neri, N E Kay, M Ferrarini, F Morabito Leukemia, 2016
Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts Irene Scarfò, Elisa Pellegrino, Elisabetta Mereu, Ivo Kwee, Luca Agnelli, Elisa Bergaggio, Giulia Garaffo, Nicoletta Vitale, Manuel Caputo, Rodolfo Machiorlatti, Paola Circosta, Francesco Abate, Antonella Barreca, Domenico Novero, Susan Mathew, Andrea Rinaldi, Enrico Tiacci, Sara Serra, Silvia Deaglio, Antonino Neri, Brunangelo Falini, Raul Rabadan, Francesco Bertoni, Giorgio Inghirami, Roberto Piva, the European T-Cell Lymphoma Study Group Blood, 2016
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia Davide Rossi, Lodovico Terzi-di-Bergamo, Lorenzo De Paoli, Michaela Cerri, Guido Ghilardi, Annalisa Chiarenza, Pietro Bulian, Carlo Visco, Francesca R. Mauro, Fortunato Morabito, Agostino Cortelezzi, Francesco Zaja, Francesco Forconi, Luca Laurenti, Ilaria Del Giudice, Massimo Gentile, Iolanda Vincelli, Marina Motta, Marta Coscia, Gian Matteo Rigolin, Alessandra Tedeschi, Antonino Neri, Roberto Marasca, Omar Perbellini, Carol Moreno, Giovanni Del Poeta, Massimo Massaia, Pier Luigi Zinzani, Marco Montillo, Antonio Cuneo, Valter Gattei, Robin Foà, Gianluca Gaidano Blood, 2015
Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment Fortunato Morabito, Giovanna Cutrona, Laura Mosca, Marianna D’Anca, Serena Matis, Massimo Gentile, Ernesto Vigna, Monica Colombo, Anna Grazia Recchia, Sabrina Bossio, Laura De Stefano, Francesco Maura, Martina Manzoni, Fiorella Ilariucci, Ugo Consoli, Iolanda Vincelli, Caterina Musolino, Agostino Cortelezzi, Stefano Molica, Manlio Ferrarini, Antonino Neri Leukemia Research, 2015
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation F Abate, M Todaro, J-A van der Krogt, M Boi, I Landra, R Machiorlatti, F Tabbò, K Messana, C Abele, A Barreca, D Novero, M Gaudiano, S Aliberti, F Di Giacomo, T Tousseyn, E Lasorsa, R Crescenzo, L Bessone, E Ficarra, A Acquaviva, A Rinaldi, M Ponzoni, D L Longo, S Aime, M Cheng, B Ruggeri, P P Piccaluga, S Pileri, E Tiacci, B Falini, B Pera-Gresely, L Cerchietti, J Iqbal, W C Chan, L D Shultz, I Kwee, R Piva, I Wlodarska, R Rabadan, F Bertoni, G Inghirami, The European T-cell Lymphoma Study Group Leukemia, 2015
Distinct patterns of global promoter methylation in early stage chronic lymphocytic leukemia Domenica Ronchetti, Giacomo Tuana, Andrea Rinaldi, Luca Agnelli, Giovanna Cutrona, Laura Mosca, Sonia Fabris, Serena Matis, Monica Colombo, Massimo Gentile, Anna Grazia Recchia, Ivo Kwee, Francesco Bertoni, Fortunato Morabito, Manlio Ferrarini, Antonino Neri Genes Chromosomes and Cancer, 2014
Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers Francesca Cottini, Teru Hideshima, Chunxiao Xu, Martin Sattler, Martina Dori, Luca Agnelli, Elisa ten Hacken, Maria Teresa Bertilaccio, Elena Antonini, Antonino Neri, Maurilio Ponzoni, Magda Marcatti, Paul G Richardson, Ruben Carrasco, Alec C Kimmelman, Kwok-Kin Wong, Federico Caligaris-Cappio, Giovanni Blandino, W Michael Kuehl, Kenneth C Anderson, Giovanni Tonon Nature Medicine, 2014
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia P Musto, V Simeon, M C Martorelli, M T Petrucci, N Cascavilla, F Di Raimondo, T Caravita, F Morabito, M Offidani, A Olivieri, G Benevolo, R Mina, R Guariglia, G D'Arena, G Mansueto, N Filardi, F Nobile, A Levi, A Falcone, M Cavalli, G Pietrantuono, O Villani, S Bringhen, P Omedè, R Lerose, L Agnelli, K Todoerti, A Neri, M Boccadoro, A Palumbo Leukemia, 2014
Clinical monoclonal B lymphocytosis versus rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features Fortunato Morabito, Laura Mosca, Giovanna Cutrona, Luca Agnelli, Giacomo Tuana, Manuela Ferracin, Barbara Zagatti, Marta Lionetti, Sonia Fabris, Francesco Maura, Serena Matis, Massimo Gentile, Ernesto Vigna, Monica Colombo, Carlotta Massucco, Anna Grazia Recchia, Sabrina Bossio, Laura De Stefano, Fiorella Ilariucci, Caterina Musolino, Stefano Molica, Francesco Di Raimondo, Agostino Cortelezzi, Pierfrancesco Tassone, Massimo Negrini, Sara Monti, Davide Rossi, Gianluca Gaidano, Manlio Ferrarini, Antonino Neri Clinical Cancer Research, 2013
Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia Domenica Ronchetti, Laura Mosca, Giovanna Cutrona, Giacomo Tuana, Massimo Gentile, Sonia Fabris, Luca Agnelli, Gabriella Ciceri, Serena Matis, Carlotta Massucco, Monica Colombo, Daniele Reverberi, Anna Grazia Recchia, Sabrina Bossio, Massimo Negrini, Pierfrancesco Tassone, Fortunato Morabito, Manlio Ferrarini, Antonino Neri BMC Medical Genomics, 2013
Improved risk stratification in myeloma using a microRNA-based classifier Ping Wu, Luca Agnelli, Brian A. Walker, Katia Todoerti, Marta Lionetti, David C. Johnson, Martin Kaiser, Fabio Mirabella, Christopher Wardell, Walter M. Gregory, Faith E. Davies, Daniel Brewer, Antonino Neri, Gareth J. Morgan British Journal of Haematology, 2013
Total body computed tomography scan in the initial work-up of Binet stage a chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study Massimo Gentile, Giovanna Cutrona, Sonia Fabris, Emanuela Anna Pesce, Luca Baldini, Francesco Di Raimondo, Caterina Musolino, Paolo Di Tonno, Nicola Di Renzo, Stefano Molica, Maura Brugiatelli, Fiorella Ilariucci, Simona Zupo, Serena Matis, Francesco Maura, Ernesto Vigna, Francesco Angrilli, Anna Grazia Recchia, Giovanni Quarta, Emilio Iannitto, Alberto Fragasso, Pellegrino Musto, Mauro Spriano, Iolanda Vincelli, Daniele Vallisa, Agostino Cortelezzi, Francesca Romana Mauro, Robin Foà, Massimo Federico, Antonino Neri, Manlio Ferrarini, Fortunato Morabito American Journal of Hematology, 2013
Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia Marta Lionetti, Pellegrino Musto, Maria Teresa Di Martino, Sonia Fabris, Luca Agnelli, Katia Todoerti, Giacomo Tuana, Laura Mosca, Maria E. Gallo Cantafio, Vitina Grieco, Gabriella Bianchino, Fiorella D'Auria, Teodora Statuto, Carmela Mazzoccoli, Luciana De Luca, Maria Teresa Petrucci, Massimo Offidani, Francesco Di Raimondo, Antonietta Falcone, Tommaso Caravita, Paola Omede', Fortunato Morabito, Pierfrancesco Tassone, Mario Boccadoro, Antonio Palumbo, Antonino Neri Clinical Cancer Research, 2013
Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth Emanuela Leone, Eugenio Morelli, Maria T. Di Martino, Nicola Amodio, Umberto Foresta, Annamaria Gullà, Marco Rossi, Antonino Neri, Antonio Giordano, Nikhil C. Munshi, Kenneth C. Anderson, Pierosandro Tagliaferri, Pierfrancesco Tassone Clinical Cancer Research, 2013
In Vitro and in Vivo Anti-tumor Activity of miR-221/222 inhibitors in multiple myeloma Maria Teresa Di Martino, Annamaria Gullà, Maria Eugenia Gallo Cantafio, Marta Lionetti, Emanuela Leone, Nicola Amodio, Pietro Hiram Guzzi, Umberto Foresta, Francesco Conforti, Mario Cannataro, Antonino Neri, Antonio Giordano, Pierosandro Tagliaferri, Pierfrancesco Tassone Oncotarget, 2013
Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles Laura Mosca, Pellegrino Musto, Katia Todoerti, Marzia Barbieri, Luca Agnelli, Sonia Fabris, Giacomo Tuana, Marta Lionetti, Eleonora Bonaparte, Silvia Maria Sirchia, Vitina Grieco, Gabriella Bianchino, Fiorella D'Auria, Teodora Statuto, Carmela Mazzoccoli, Luciana De Luca, Maria Teresa Petrucci, Fortunato Morabito, Massimo Offidani, Francesco Di Raimondo, Antonietta Falcone, Tommaso Caravita, Paola Omedè, Mario Boccadoro, Antonio Palumbo, Antonino Neri American Journal of Hematology, 2013
Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia Sonia Fabris, Laura Mosca, Giovanna Cutrona, Marta Lionetti, Luca Agnelli, Gabriella Ciceri, Marzia Barbieri, Francesco Maura, Serena Matis, Monica Colombo, Massimo Gentile, Anna Grazia Recchia, Emanuela Anna Pesce, Francesco Di Raimondo, Caterina Musolino, Marco Gobbi, Nicola Di Renzo, Francesca Romana Mauro, Maura Brugiatelli, Fiorella Ilariucci, Maria Grazia Lipari, Francesco Angrilli, Ugo Consoli, Alberto Fragasso, Stefano Molica, Gianluca Festini, Iolanda Vincelli, Agostino Cortelezzi, Massimo Federico, Fortunato Morabito, Manlio Ferrarini, Antonino Neri American Journal of Hematology, 2013
Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: In vitro and in vivo evidence Maria T. Di Martino, Emanuela Leone, Nicola Amodio, Umberto Foresta, Marta Lionetti, Maria R. Pitari, Maria E. Gallo Cantafio, Annamaria Gullà, Francesco Conforti, Eugenio Morelli, Vera Tomaino, Marco Rossi, Massimo Negrini, Manlio Ferrarini, Michele Caraglia, Masood A. Shammas, Nikhil C. Munshi, Kenneth C. Anderson, Antonino Neri, Pierosandro Tagliaferri, Pierfrancesco Tassone Clinical Cancer Research, 2012
Primary plasma cell leukemia in the era of new drugs: Has something changed? Pellegrino Musto, Livio Pagano, Maria Teresa Petrucci, Fortunato Morabito, Tommaso Caravita, Francesco Di Raimondo, Luca Baldini, Patrizia Tosi, Sara Bringhen, Massimo Offidani, Paola Omede’, Antonino Neri, Fiorella D’Auria, Giovanni Battista Bochicchio, Michele Cavo, Mario Boccadoro, Antonio Palumbo Critical Reviews in Oncology Hematology, 2012
DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma Nicola Amodio, Marzia Leotta, Dina Bellizzi, Maria Teresa Di Martino, Patrizia D’Aquila, Marta Lionetti, Fernanda Fabiani, Emanuela Leone, Anna Maria Gullà, Giuseppe Passarino, Michele Caraglia, Massimo Negrini, Antonino Neri, Antonio Giordano, Pierosandro Tagliaferri, Pierfrancesco Tassone Oncotarget, 2012
The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia Fortunato Morabito, Rosaria De Filippi, Luca Laurenti, Katja Zirlik, Anna Grazia Recchia, Massimo Gentile, Emanuela Morelli, Ernesto Vigna, Vincenzo Gigliotti, Rosa Calemma, Barbara Amoroso, Antonino Neri, Giovanna Cutrona, Manlio Ferrarini, Stefano Molica, Giovanni Del Poeta, Claudio Tripodo, Antonio Pinto Blood, 2011
The clinical and biological features of a series of immunophenotypic variant of B-CLL Lilla Cro, Andrea Ferrario, Marta Lionetti, Francesco Bertoni, Nadia Zucal N, Lucia Nobili, Sonia Fabris, Katia Todoerti, Agostino Cortelezzi, Andrea Guffanti, Maria Goldaniga, Luigi Marcheselli, Antonino Neri, Giorgio Lambertenghi‐Deliliers, Luca Baldini European Journal of Haematology, 2010
Critical analysis of transcriptional and post-transcriptional regulatory networks in multiple myeloma Pacific Symposium on Biocomputing 2010 Psb 2010, 2010
Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis Giancarlo Pruneri, Alessandra Alietti, Luca Agnelli, Fortunato Morabito, Daniele Laszlo, Liliana Calabrese, Sonia Fabris, Francesco Bertolini, Alberto Agazzi, Luca Bottiglieri, Paola Rafaniello Raviele, Luca Baldini, Stefano Pileri, Elena Sabattini, Silvano Bosari, Patrick Maisonneuve, Giorgio Lambertenghi-Deliliers, Francesco Bertoni, Giovanni Martinelli, Giuseppe Viale, Antonino Neri Leukemia Research, 2008
Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia Sonia Fabris, Laura Mosca, Katia Todoerti, Giovanna Cutrona, Marta Lionetti, Daniela Intini, Serena Matis, Monica Colombo, Luca Agnelli, Massimo Gentile, Mauro Spriano, Vincenzo Callea, Gianluca Festini, Stefano Molica, Giorgio Lambertenghi Deliliers, Fortunato Morabito, Manlio Ferrarini, Antonino Neri Genes Chromosomes and Cancer, 2008
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib Roberto Piva, Bruce Ruggeri, Michael Williams, Giulia Costa, Ilaria Tamagno, Dario Ferrero, Valentina Giai, Marta Coscia, Silvia Peola, Massimo Massaia, Gabriella Pezzoni, Cecilia Allievi, Nicoletta Pescalli, Mara Cassin, Stefano di Giovine, Paola Nicoli, Paola de Feudis, Ivan Strepponi, Ilaria Roato, Riccardo Ferracini, Benedetta Bussolati, Giovanni Camussi, Susan Jones-Bolin, Kathryn Hunter, Hugh Zhao, Antonino Neri, Antonio Palumbo, Celia Berkers, Huib Ovaa, Alberto Bernareggi, Giorgio Inghirami Blood, 2008
BCL-6 mutations are associated with immunoglobulin variable heavy chain mutations in B-cell chronic lymphocytic leukemia Cancer Research, 2000
Detection of t(4;14)(p16.3;q32) Chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts Cancer Research, 2000
Posttransplantation cutaneous B-cell lymphoma with monoclonal epstein- barr virus infection, responding to acyclovir and reduction in immunosuppression Journal of Heart and Lung Transplantation, 1997
MDM-2 oncoprotein overexpression in laryngeal squamous cell carcinoma: Association with wild-type p53 accumulation Modern Pathology, 1997
Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: Correlation with in vitro sensitivity to chlorambucil and purine analogs Haematologica, 1997
Analysis of alterations of oncogenes and tumor suppressor genes in chronic lymphocytic leukemia American Journal of Pathology, 1994
Mechanism of expression and role in transcriptional control of the proto-oncogene NFKB-2/LYT-10 Oncogene, 1994
Analysis of p53 and gene mutations in endometriosis Paolo Vercellini, Dino Trecca, Sabina Oldani, Nicola S. Fracchiolla, Antonino Neri, Pier Giorgio Crosignani Gynecologic and Obstetric Investigation, 1994
Mutations in the coding region of c-myc occur independently of mutations in the regulatory regions and are predominantly associated with myc/Ig translocation Current Topics in Microbiology and Immunology, 1994
Analysis of p53 gene mutations in acute myeloid leukemia Dino Trecca, Letizia Longo, Andrea Biondi, Lilla Cro, Rossella Calori, Fausto Grignani, Anna Teresa Maiolo, Pier Giuseppe Pelicci, Antonino Neri American Journal of Hematology, 1994
p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia Proceedings of the National Academy of Sciences of the United States of America, 1991
Defective granulocyte chemotaxis and natural killer activity in a patient with recurrent infections Journal of Clinical and Laboratory Immunology, 1986
Lymphocyte subsets in idiopathic thrombocytopenic purpura: Relationship with disease activity and therapy Current Therapeutic Research Clinical and Experimental, 1984
Analysis of the enzyme terminal deoxyribonucleotidyl transferase in lymphoma and leukemia cells Acta Bio Medica De L Ateneo Parmense Organo Della Societa Di Medicina E Scienze Naturali Di Parma, 1984
Clinical stage and immunological findings in chronic lymphocytic leukemia. Bollettino Dell Istituto Sieroterapico Milanese, 1984
Presence of circulating immune complexes in patients with chronic lymphocytic leukaemia. Correlations between clinical and immunological features Bollettino Dell Istituto Sieroterapico Milanese, 1982
